DaVita Inc.

- No specific mention of new fundraising through debt or equity in the call. - Debt expense for 2026 is expected to be about flat to last year, with quarterly debt expense similar to Q1 levels. - Share repurchases totaled 3 million shares in Q1 plus an additional 2 million shares post-quarter, including shares bought from Berkshire Hathaway under a repurchase agreement. - Leverage ratio at end of Q1 was 3.34x consolidated EBITDA, within target range of 3 to 3.5x. - The company appears focused on share repurchases rather than new equity issuance. - No indications of plans for new debt issuance; current debt expense guidance suggests stable debt levels.

- DaVita is making targeted technology investments to expand their IT systems and digital infrastructure, empowering clinical teams and supporting future clinical and operational excellence. - Continued investment in AI solutions and data infrastructure modernization, including their proprietary EMR platform, to enhance clinical, operational, and business use cases. - Example given: deployment of ScheduleHub, a tool for optimizing patient and staffing schedules in real time, aiming to reduce administrative burden and improve teammate experience. - These tech investments are reflected in a 13% increase in G&A costs year-over-year due to sustained IT investment. - The approach to technology is long-term, focused on sustainability and outperformance rather than immediate timing of cost savings. - There's ongoing focus on optimizing total costs, including patient care, depreciation, amortization, and G&A, with a total cost CAGR of 2.6% over the past five years.

- Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures. - Treatments per normalized day expected to grow 50-75 basis points in 2026. - Revenue per treatment (RPT) growth forecast remains 1% to 2% for the full year despite Q1 being about 4% higher due to timing effects. - Commercial mix is expected to decline over the year, potentially pressuring RPT. - Technology investments and AI deployment aim to improve operational efficiency and clinical outcomes, supporting sustainable volume and revenue growth. - Long-term focus on maintaining 3% to 7% operating income growth by balancing efficiency and clinical excellence.

- DaVita raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, driven primarily by higher treatment volume and lower patient care costs. - Adjusted EPS guidance was raised to a range of $14.10 to $15.20 per share, reflecting the improved operating income outlook. - The volume growth expectation was increased from flat to a range of 25 to 50 basis points growth, supported partly by patient transfers from Fresenius clinic closures. - Operating income growth is targeted to be sustained at 3% to 7% over time, emphasizing long-term efficiency and investment in clinicians. - Free cash flow guidance remains unchanged due to higher variability despite earnings growth. - Investments in technology and AI are expected to support sustainable outperformance and clinical and operational excellence in the long term.

The provided transcript does not mention any specific details regarding current or expected order book or pending orders for DaVita Inc. The discussion focuses primarily on financial performance, treatment volumes, clinical outcomes, technology investments, ACA Plan enrollment, operating income guidance, and volume growth expectations. There is no information related to order books or pending orders in the Q1 2026 earnings call.